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Background: Transcatheter aortic valve implantation (TAVI) has been established as a treatment option for
inoperable patients with symptomatic aortic valve stenosis. However, patients suffer frequently from conduction
disturbances after TAVI.
Methods: Baseline, procedural as well as surface and intracardiac ECG parameters were evaluated for patients
treated with TAVI and a comparison between patients requiring pacemaker with those not suffering from relevant
conduction disorders were done.
Results: TAVI was successfully in all patients (n=45). Baseline surface and intracardiac ECG recording revealed longer
PQ (197.1±51.2 msec versus 154.1±32.1 msec; p<0.001), longer AH (153.6±43.4 msec versus 116.1±31.2 msec;
p<0.001) and HV interval (81.7±17.8 msec versus 56.8±8.5 msec; p<0.001) in patients with need for a pacemaker
(n=23) versus control group (n=22); furthermore, 7-day follow-up analysis showed a higher prevalence of new left
bundle branch block (LBBB) (87.0% versus 31.9%; p<0.001). Multivariate analysis revealed that only new LBBB, QRS
duration >120 msec and a PQ interval >200 msec immediately (within 60 minutes) after implantation of the aortic
valve were predictors for high-grade (type II second-degree and third-degree) AV block. Other clinical parameters as
well as baseline electrocardiographic parameters had no impact on critical conduction delay.
Conclusion: Cardiac conduction disturbances are common after TAVI. The need for pacing after TAVI is predictable
by surface ECG evaluation immediately (within 60 minutes) after the procedure.
Keywords: TAVI, AV block, Left bundle branch block, Pacemaker, His bundleBackground
Transcatheter aortic valve implantation (TAVI) has
emerged as an alternative to open surgery in patients
with symptomatic aortic valve stenosis considered at
high risk or unsuitable for thoracotomy [1,2]. Atrioven-
tricular (AV) block with subsequent pacemaker require-
ment was described in 6% of cases after surgical aortic
valve replacement, but varies after TAVI between 5.7%
and 42.5%, while new left bundle branch block (LBBB)
occurs in up to 50-70% [2-6]. Moreover, early prediction
of pacemaker requirement after TAVI would be of* Correspondence: ibrahim.akin@med.uni-rostock.de
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reproduction in any medium, provided the orpotential benefit by shortening both postoperative moni-
toring and hospitalization. We compared both clinical
parameters as well as surface and intracardiac ECG
recordings prior and after TAVI and analyzed differences
in patients eventually requiring permanent pacing after
TAVI for relevant conduction delay.Methods
Patients
In our retrospective analysis, between January 2007 and
January 2008 45 patients without previously known pace-
maker who underwent TAVI using the third-generation
percutaneous self-expanding CoreValve prosthesis
(Medtronic Inc; Minneapolis, USA) were identified for
this analysis. The criteria for inclusion and exclusion to
the TAVI procedure have been described elsewhere [1-4].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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measurements of severe native valvular stenosis and an
area < 1 cm2, or < 0.6 cm2/m2 regardless of adjunct valvu-
lar regurgitation; a diameter of basal orifice of the sten-
osed valve between 20 and 27 mm; and a diameter
at the sinutubular junction ≤ 43 mm. Most import-
antly, all patients were considered unfit for open surgery
with an EuroSCORE ≥ 20% [7]. TAVI was suggested in
agreement between a cardiac surgeon and both, a clin-
ical and interventional cardiologist; patient`s or referring
physician`s preference was not relevant [8,9]. Treatment
strategy was in compliance with the Helsinki Declar-
ation. Our local ethics committee approved this treat-
ment strategy. Patients gave informed consent prior
TAVI. Pacemaker implantation at follow-up was con-
sidered indicated in case of complete AV-block, type II
second-degree AV block, and in presence of new LBBB
in combination with HV prolongation ≥ 75 msec. We
compared patients requiring a new pacemaker within 7
days with those not requiring any pacemaker and no
significant conduction delay after TAVI.
Procedure
Details of the implantation technique have been
described elsewhere [1-4]. In brief, all procedures were
performed in an interventional hybrid suite under gen-
eral anaesthesia to assure stable hemodynamic and
minimize patient movement. TAVI was performed via
femoral access under fluoroscopy; the aortic valve was
initially dilated using a standard valvuloplasty balloon
with a nominal diameter similar to the aortic valve
and followed by CoreValve (Medtronic Inc.) insertion
[1,3-6]. In each patient, prior to TAVI and aside a
right ventricular bipolar pacing lead (Pacel™, St. Jude
Medical, St Paul, MN, USA), a 6F quadripole electrode
catheter with ring electrodes (5-mm interpole distance)
(Webster D™, Biosense Webster, Diamond, USA) was
introduced and advanced to the His bundle. A 6F
quadripolar electrode catheter (Soloist™, Medtronic,
Minneapolis, MN, USA) was advanced to the right
atrium and another to the right ventricle to record a
bipolar electrogram and for programmed atrial and
ventricular stimulation. The access sites for all electro-
physiologic electrode catheters were the femoral veins.
With such instrumentation the sinus node recovery
time (SNRT), corrected sinus node recovery time (c-
SNRT), antegrade and retrograde effective refractory
period (ERP) of the AV node, as well as intracardiac
conduction times (atrium to His and His to ventricle
time; AH and HV interval) were assessed. The rational
to measure SNRT was the observations of sinus node
arrest in a single patient receiving a CoreValve prior
this study. Thus, we wanted to avoid oversee sinus
node pathology in this elderly patients suffering from ahigh comorbidity index. All measurements were done
on an Axiom Sensis™ (Siemens, Erlangen, Germany)
electrophysiology workstation prior to the valve im-
plantation, immediately after valve implantation and at
a follow-up of 7 days. The AV nodal ERP was mea-
sured by introducing a single extrastimulus (S2) after a
drive train of 8 stimuli at a fixed rate (S1) (600ms), at
which time the S1-S2 interval is decreased until the S2
impulse does not conduct to the His bundle. To assess
conduction disorders, patients were attached to un-
interrupted ECG monitoring using the Philips monitor-
ing system (IntelliVue™, Best, The Netherlands) that is
installed at our ICU/IMC unit. All patients were
prophylactically given a temporary pacemaker via the
existing femoral venous access; with VVI mode the ac-
tive pacing was 60 bpm for at least 24 hours.
Statistical methods
All data were stored and analysed using SPSS statistical
package 17.0 (Chicago, Illinois, USA). The statistics
computed included mean and standard deviations of
continuous variables and are presented as means ± SD,
frequencies and relative frequencies of categorical fac-
tors. The Fisher exact test and chi2-test were used to
compare proportions. A normal distribution of differ-
ences was confirmed by the Kolmogorov-Smirnov test;
in presence of normally distributed data the t-test was
used while with non-normal distribution the Mann–
Whitney U-test was applied. The logistic regression
model was used to assess the interdependence of high-
grade AV block (type II second-degree and third-degree)
at 7 day follow-up from prognostic factors. First, uni-
variate analyses were performed to reveal unadjusted sig-
nificant associations between prognostic variables and
high-grade AV block. Thereafter, variables yielding
p-values ≤ 0.25 with univariate analysis were entered
in the multivariate model to assess adjusted associa-
tions between outcomes and covariates which were
univariate and of borderline significance. All p-values
resulted from two-sided statistical tests and ≤ 0.05 was
considered to be significant.
Results
The analysis included 18 men and 27 women at a mean
age of 81.5±6.8years with severe aortic valve stenosis
and no previously known pacemaker. All patients had
qualified for TAVI following recent recommendations
[8,9]. We compared patients requiring new pacemaker
implantation during hospital stay (n=23) with those not
suffering from relevant conduction delays (n=22) in the
attempt to elucidate predictors for pacing. Smokers
(34.8% versus 18.2%; p=0.024) as well as patients suffer-
ing from angina, with ischemic heart disease, previous
stroke or peripheral arterial disease were more frequent
Table 1 Baseline characteristics of study population








Male, n (%) 10 (43.5) 8 (36.4) 0.763
Age (yrs) 80.7 ± 5.94 81.55 ± 7.90 0.684
Body mass index (kg/m2) 26.9 ± 3.9 26.8 ± 4.0 0.883
Hypertension, n (%) 22 (95.7) 19 (86.4) 0.346
Smoker, n (%) 8 (34.8) 4 (18.2) 0.024
Diabetes mellitus, n (%) 10 (43.5) 7 (31.8) 0.542
Creatinine (μmol/l) 151.2 ± 157.4 114.3 ± 51.6 0.372
Renal insufficiency
(creatinine level > 1.5mg/dl),
n (%)
14 (60.9) 11 (50) 0.554
Chronic obstructive
pulmonary disease, n (%)
4 (17.1) 4 (18.2) 0.855
New York Heart Association functional class
I 0 (0) 0 (0) 0.263
II 0 (0) 2 (9.1)
III 15 (65.2) 15 (68.2)
IV 8 (34.8) 5 (22.7)
Logistic EuroSCORE (%) 24.0 ± 14.6 18.4 ± 19.2 0.034
Dyspnoe, n (%) 13 (56.6) 12 (54.6) 0.628
Angina, n (%) 11 (47.5) 6 (27.3) 0.022
Syncope, n (%) 3 (13.0) 8 (36.4) 0.091
Pulmonal artery pressure (mmHg) 42.8 ± 17.7 37.6 ± 19.9 0.375
Porcelain aorta, n (%) 1 (4.3) 3 (13.6) 0.346
Prior cardiac decompensation, n (%) 13 (56.5) 14 (63.7) 0.763
Ischemic heart disease, n (%) 20 (87.0) 15 (68.2) 0.017
Previous stroke, n (%) 10 (43.5) 3 (13.6) 0.047
Previous CABG, n (%) 1 (4.3) 2 (9.1) 0.838
Peripheral vessel disease, n (%) 5 (21.7) 1 (4.6) 0.002
Echocardiographic parameters
Mean aortic valve area (cm2) 0.8 ± 0.2 0.7 ± 0.2 0.108
Left ventricular ejection
fraction (%)
46.1 ± 10.7 50.2 ± 12.5 0.224
Peak pressure gradient (mmHg) 90.6 ± 24.1 86.6 ± 27.9 0.641
Mean pressure gradient (mmHg) 57.7 ± 15.3 55.4 ± 15.6 0.674
Aortic annulus dimension (mm) 23.30 ± 5.32 22.36 ± 6.85 0.141
Aortic bulbus dimension (mm) 29.70 ± 5.86 28.61 ± 7.46 0.893
Interventricular septal
dimension (mm)
14.17 ± 3.82 13.55 ± 2.46 0.627
Aortic regurgitation grade ≥ I, n (%) 19 (82.6) 20 (90.9) 0.692
Mitral insufficiency ≥ grade I, n (%) 22 (95.7) 19 (86.4) 0.247
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operative mortality estimate was higher in patients re-
quiring a pacemaker compared to the non-pacemaker
group (24.0±14.6% versus 18.4±19.2%; p=0.034). Echo-
cardiographic measurements on aortic stenosis severity
and left ventricular function as well as intraoperative
data revealed similar findings in both groups (Table 1).
TAVI was successfully performed in all patients with a
mean procedural time of 107.7±27.1 min and 104.9±33.3
min (p=0.725); length of stay in intensive care unit and
in-hospital stay was similar in both groups. Six patients
suffered from intraprocedural circulatory depression and
required transient intravenous pressors; 1 patient
required 1 DC shock for ventricular fibrillation during
wire navigation of the calcified aortic stenosis. Post-
interventional aortography revealed similar grades of
aortic insufficiency (Table 2).
The incidence of conduction delay requiring pace-
maker implantation during 7-day follow-up after TAVI
was 51.1% (n=23) due to complete AV block in 13.3%
(n=6), type II second-degree AV block in 8.9% (n=4) and
due to combined new LBBB with prolongation of HV
interval ≥ 75 msec in 28.8% (n=13) (Table 3) (Figure 1).
Baseline surface and intracardiac ECG recording
revealed longer PQ interval of 197.1±51.2 msec versus
154.1±32.1 msec (p<0.001) caused by longer AH and
HV intervals in the pacemaker group (Figure 2). Evalu-
ation within 60 minutes after TAVI and at 7-day post
TAVI, which was done in all patients, revealed a higher
prevalence of new LBBB in pacemaker group with 87.0%
versus 31.9% (p<0.001), as well as longer intervals for
PQ, AH and HV interval (p<0.001). Similarly, QRS dur-
ation and antegrade and retrograde ERP were higher in
pacemaker group (p<0.001) without any differences in
SNRT or rates of right bundle branch block. Of 22
patients suffering from first-degree AV block 18 demon-
strated prolonged HV interval (13 patients with a pro-
longation to ≥ 75 msec and 5 with a prolongation to
< 75 msec), while 8 patients revealed a prolongation of
AH interval without progression to complete heart
block. Similarly, 5 patients with prolongation of HV
interval to < 75 msec received no pacemaker (Table 3).
A multivariate analysis to identify predictors for high-
grade AV block (type II second-degree and third-degree)
resulting in pacemaker requirement included baseline
clinical, electrocardiographic and echocardiographic
parameters. With evolution to high-grade AV block as a
hard endpoint in this model the univariate analysis
revealed new LBBB immediately (within 60 minutes)
after TAVI (OR 7.67; 95% CI 1.40-41.94; p=0.01), as well
as PQ interval > 200 msec (OR 14.00; 95% CI 1.51-
130.01; p=0.02) and QRS duration > 120 msec (OR
13.80; 95% CI 1.535-118.69; p=0.019) as predictors for
high-grade AV block during hospital stay. Similarly, themultivariate model revealed new LBBB immediately
(within 60 minutes) after TAVI (OR 24.85; 95% CI 1.57-
392.57; p=0.023), as well as PQ interval > 200 msec (OR
11.37; 95% CI 1.138-97.620; p=0.02) and QRS > 120
msec (OR 14.28; 95% CI 1.50-135.88; p=0.021) as
Table 3 Electrocardiographic characteristics
Prior TAVI After TAVI 7-day
follow-up
Rhythm
Sinus 18 (78.3) 18 (78.3) 14 (63.7)
20 (91.0) 20 (91.0) 19 (82.7) *
Atrial fibrillation 5 (21.8) 5 (21.8) 5 (21.8)
2 (9.1) 2 (9.1) 5 (9.1)
Heart rate 72.7 ± 12.6 68.5 ± 13.8 66.0 ± 16.9
67.5 ± 10.5 63.2 ± 14.4 65.7 ± 13.1
Surface ECG
PQ interval 197.1 ± 51.2 230.42 ± 40.94 243.05 ± 34.59
154.1 ± 32.1 * 167.37 ± 37.05 * 168.56 ± 30.41 *
QRS width 97.0 ± 15.0 139.04 ± 31.86 162.96 ± 33.59
95.3 ± 14.4 110.27 ± 18.38 * 120.00 ± 24.17 *
QT interval 388.2 ± 29.3 409.91 ± 28.67 408.52 ± 23.22
398.6 ± 32.8 407.36 ± 32.99 405.14 ± 32.03
Left-BBB 0 (0) 16 (69.6) 20 (87.0)
1 (4.5) 4 (18.2) * 7 (31.9) *
Right-BBB 1 (4.35) 0 (0) 0 (0)
1 (4.5) 1 (4.6) 1 (4.6)
First-degree
block
5 (21.8) 8 (34.8) 18 (78.3)
3 (13.7) * 3 (13.7) * 4 (18.2) *
Second-degree
block #
0 (0) 4 (17.4) 4 (17.4)
0 (0) 0 (0) * 0 (0) *
Table 2 Intraoperative data of pacemaker (PM) and non
pacemaker group (N-PM)
PM N-PM p
Procedural success, n (%) 23 (100) 22 (100) 0.999
Conversion to surgical AVR, n (%) 0 (0) 0 (0) 0.999
Intraprocedural circulatory
depression, n (%)
4 (17.4) 2 (9.1) 0.635
Catecholamine therapy, n (%) 4 (17.4) 2 (9.1) 0.714
Resuscitation, n (%) 1 (4.4) 0 (0) 0.553
Defibrillation, n (%) 1 (4.4) 0 (0) 0.612
Vascular access site
complication, n (%)
5 (21.8) 4 (18.2) 0.367
Contrast agent (ml) 113.3 ± 36.4 125.5 ± 60.8 0.732
Fluoroscopy time (min) 25.7 ± 1.8 23.9 ± 2.6 0.572
Procedure time (min) 107.7 ± 27.1 104.9 ± 33.3 0.725
CoreValve, n (%)
26mm 10 (43.5) 12 (54.6) 0.112
29mm 13 (56.6) 10 (45.5) 0.386
Pre TAVI, n (%) 23 (100) 22 (100) 0.999
Post TAVI valvuloplasty, n (%) 10 (43.5) 10 (45.5) 0.566
Number of inflations, n (%) 1.08 ± 0.75 1.14 ± 0.94 0.335
Balloon diameter (mm) 21.87 ± 3.84 21.27 ± 4.44 0.432
Balloon length (mm) 55.22 ± 26.81 52.73 ± 30.27 0.613
Angiographic Aortic
insufficiency (grade)
1.22 ± 0.48 1.10 ± 0.62 0.725
ICU stay (days) 2.9 ± 3.2 2.5 ± 1.8 0.686
Hospital stay (days) 13.4 ± 11.3 12.0 ± 6.5 0.237
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meters as well as baseline electrocardiographic para-
meters (e.g. AH interval > 100ms, HV interval > 75ms,
QRS > 120ms and PQ >200ms) had no impact to predict
critical conduction delay (Tables 1, 2, 3).Complete
block
0 (0) 4 (17.4) 6 (26.1)
0 (0) 0 (0) * 0 (0) *
Intracardiac measurement
SNRT 1086.8 ± 171.2 1093.89 ± 154.58 1122.11 ± 154.47
1045.6 ± 166.9 1050.56 ± 163.40 1070.59 ± 154.13
c-SNRT 487.0 ± 54.3 492.94 ± 43.88 498.13 ± 42.72
462.0 ± 68.4 491.12 ± 42.04 488.59 ± 42.48
AH interval 135.5 ± 44.7 139.32 ± 36.62 153.61 ± 43.40
105.8 ± 31.4 * 114.50 ± 38.55 * 116.06 ± 31.23 *
HV interval 58.5 ± 12.5 74.00 ± 13.51 81.68 ± 17.76
48.7 ± 6.9 * 55.27 ± 9.20 * 56.76 ± 8.45 *
Antegrade
AV ERP
410.0 ± 42.6 470.00 ± 118.57 469.81 ± 45.75
394.4 ± 32.6 407.78 ± 32.64 * 414.71 ± 31.45 *
Retrograde
AV ERP
442.6 ± 38.0 470.56 ± 45.10 494.00 ± 59.33




# 2nd degree (type 2) AV-block.Discussion
TAVI is established as an option with reduced morbidity
and mortality in high risk symptomatic patients unfit for
open surgery [10-14]. Considering the proximity of aor-
tic valve annulus to conduction system, both open sur-
gery and TAVI may impact on both AV node and His
bundle conduction.
While complete AV block was reported in 5.7%, new
LBBB occurred in 18% with an association to complete
AV block, syncope, and sudden cardiac arrest at long
term after open surgery [15-17]. Risk factors for
complete AV block after surgical aortic valve replace-
ment include previous aortic regurgitation, myocardial
infarction, pulmonary hypertension, and postoperative
electrolyte imbalance [16,17], among ECG criteria right
bundle branch block (RBBB) on surface ECG was the
strongest predictor for pacemaker requirement [16,17].Although previous investigations report changes in
surface-ECG after TAVI [2,10-14], our group was the
first to describe intracardiac conduction abnormalities
for better discrimination of new ECG changes on sur-
face-ECG, and to predict critical conduction delays [18].
In our series, complete AV block was seen in 13.3%,
Figure 1 Rate of LBBB and AV block in pacemaker and non pacemaker group prior and 7 days after TAVI.
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block; thus, 22.2% of patients developed an indication
for permanent pacemaker implantation corroborating
previous findings [10-14,19-23]. Additionally, 28.9%Figure 2 AH and HV conduction time in pacemaker and non pacemakpatients received a pacemaker for new LBBB combined
with a marked prolongation of the HV interval to ≥ 75
msec for primary prevention. Such indication may be
debatable, but due to the lack of data and due to theer group prior and 7 days after TAVI.
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bidities preventive pacemaker use appears justified [24].
Jilaihawi et al. reported first that pacemaker require-
ment after TAVI correlates to left axis deviation at
baseline, LBBB, baseline thickness of the native non-
coronary cusp and to diastolic interventricular septal
dimension > 17mm [13]. Similarly, Piazza et al.
revealed no prosthesis-related LBBB when the proximal
end of the valve frame was positioned < 6.7mm from
the lower edge of the non-coronary cusp [10]. Dege-
nerative calcification of the aortic and mitral annulus
is probably a diffuse process, in which the cardiac
conduction system is often involved and making it
vulnerable to injury when exposed to mechanical
compression by the nitinol frame of the CoreValve,
which seems to completely expand within the first 7–
10 days [14]. Differences to surgical aortic valve re-
placement might be due to the different techniques.
In surgical approach the valve is replaced by another.
Thus, the amount of conduction damage is predict-
able because the local trauma is nearly the same in
all patients. However, in TAVI the amount of local
damage is dependent of local calcification, the height
of implantation in LVOT, the extend of trauma dur-
ing index-procedure (balloon valvuloplasty, balloon-
to-aortic annulus relation, post-TAVI dilatation) and
from further aortic annulus geometry.
Our intracardiac measurements revealed that occur-
rence of first-degree AV block were predominantly due
to prolongation of HV interval, which might be prognos-
tically relevant [24]. We implanted pacemaker in
patients with new LBBB and a HV prolongation to ≥ 75
msec in a somewhat liberal fashion in this patients with
high comorbidity index. In contrast, our multivariate
analysis revealed that only a PQ duration > 200 msec, a
LBBB and a QRS duration > 120 msec immediately
(within 60 minutes) after CoreValve implantation seem
to predict critical AV conduction delay. Other baseline
clinical and ECG parameters had no impact. The occur-
rence of above ECG findings soon after TAVI may
reflect the extent of trauma from the procedure. Inter-
estingly, the exact determination of both the amount
of valve calcification and the height of implantation
turned out to be non-reproducible although both para-
meters have been claimed to impact on conduction
physiology [10,13]. For example, the Edwards SAPIEN
valve, shorter and less likely to extend into the left
ventricular outflow tract, is obviously associated with a
lower rate of complete AV block (0-6%) [25,26]. As
demonstrated by our results, we believe that regardless
of favourable anatomy only the extent of trauma pre-
dict the occurrence of critical conduction delay after
TAVI. According to our multivariate analysis HV pro-
longation ≥ 75 msec is not a predictor for pacemakerrequirement. We have implanted since 2007 nearly 400
aortic valves. Our pacemaker rate was initially about
45%. This was due to the novelty of this technique
and lack of information regarding the true indication
for pacing. However, with further analysis of patients
and improving implantation techniques (e.g. high im-
plantation technique, no further post-TAVI balloon
dilatation) our pacing rate decreased to 9-10%. Based
on our data we decided not to perform routinely intra-
cardiac measurements. The presence of a new left
bundle branch block in case of normal AV conduction
on surface ECG in not an indication for pacing. For
clinical routine, a surface 12-lead ECG immediately
(within 60 minutes) after the TAVI procedure may in-
dicate the need for pacemaker without incremental in-
formation from intracardiac ECG recordings, the
quantification of aortic valve calcification, septal thick-
ness or height of implantation.
Conclusion
TAVI is feasible and safe in patients unfit for open surgi-
cal aortic valve replacement. Due to the proximity of the
implanted valve structure to the septum, conduction dis-
turbances are common after TAVI requiring close sur-
veillance at least for 7 days after TAVI. The occurrence
of complete and type II second-degree AV block is pre-
dictable by a new LBBB, a PQ duration > 200 msec and
QRS duration > 120 msec soon after TAVI and reflect
the extent of trauma to the conduction system. Yet, the
occurrence of new LBBB combined with first-degree AV
block, reflecting prolongation of the HV interval, is fre-
quent and should be subjected to further study.
Study limitation
The present study suffers from the limitation of being a
retrospective analysis. Additionally, the low number of
patients may influence the results. However, our study
showed that there might be no further information from
intracardiac measurements as the ECG changes predom-
inantly present as LBBB, first grade and complete AV
block. The differentiation of AV block in supra-His and
infra-His is not essential in these frailty patients with
high comorbidity index. Thus, there will always be a
somewhat “liberal” indication for pacemaker implant-
ation. To date, there is a need for further larger scale
prospective trials as well as registries with longer follow-
up for predicting factors for pacemaker requirement and
defining the role and duration of ECG changes.
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